Drug treatments from
Both firms tested drugs that harness a patient`s immune system to fight cancer. A regimen of Bristol`s Opdivo and Yervoy, two immuno-oncology drugs, cut the risk of cancer progression or death by 42% compared with chemotherapy.
Merck`s regimen, however, used a combination of Keytruda and chemotherapy. That reduced the risk of death by 51%.
In early trading on the stock market today, Bristol tanked 5.2%, near 55.60.
(c) 2018 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source
Source : http://www.4-traders.com/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Topples-After-Merck-Treatment-Outperforms-It-In-Lung-Cancer-Tests-26369303/165